Israel's Health Spending in 1992

9 October 1994

In 1992, Israel's expenditure on health reached 7.7% of Gross Domestic product and 9% of government spending. National health care spending rose 2% per capita, following two years when the spending rise did not keep up with the rise in population resulting from the influx of immigrants from the former USSR.

Households financed 52% of national health spending in 1992, up from 47%-49% in 1987-91, due to a rise in membership fees paid to sick funds to 23% of total spending, up from 20% in 1991 and 18%-19% in the four previous years. However, the sick funds' deficit financing shrank. Households' payments for services from government and public institutions remained at 7% of the total, and payments for medicines and services from the business sector remained at 22%.

Government financing including the parallel tax was 46%-47% of the total in 1989-92, down from 50% in 1987-88 and 54% in 1985 and 1986, due to fewer parallel tax transfers to sick funds. Government financing other than by the tax changed little; direct financing of services from government hospitals and institutions and direct investment in buildings and equipment was 17%-19% of the total. Government support for non-profit health institutions accounted for 2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight